Efficient expression system of SARS-CoV-2 receptor binding domain (RBD), methods for purification and use thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 31, 2023
Grant Date -
N/A
app pub date -
Jan 25, 2022
filing date -
Aug 20, 2021
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to the production of the receptor binding domain (RBD) of the Spike glycoprotein 1 of the SARS-CoV-2 in mammalian cell expression systems, and the successive method of purification thereof. A recombinant plasmid containing the coding sequence of said RBD is produced and transfected in said mammalian cells, for example, Expi293. A high level of the protein is secreted in the medium and subsequently purified using the N-terminal tag, that can be removed by a specific protease. The present invention also includes a recombinant expression vector carrying the RBD gene, the successive methods for protein purification, the strategy for establishing a stable cell line producing the RBD, methods of use of the recombinant protein in formulating a pharmaceutical composition, including but not limited to, vaccines for preventing SARS-CoV-2 induced diseases.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully